First-Line Use of Ruxolitinib and Dosing Modifications in Patients With Polycythemia Vera

Two abstracts presented at the 2019 American Society of Hematology Annual Meeting highlight the use of ruxolitinib in patients with polycythemia vera who are newly diagnosed and those previously treated with hydroxyurea.

American Journal of Managed Care